Cairo-based Pharmacy delivery platform Chefaa raised seven-figure Pre-Series A round from 500 startups, Vision Ventures, womena, and others. The investment will be used to grow its operations team in order to provide users with around the clock assistance.
Doaa Aref & Rasha Rady co-founded Chefaa in 2017. Chefaa connects patients & pharmacies and allows chronic patients to order, schedule and refill their recurring prescriptions and all relevant non-pharmaceuticals. It manages all patients’ pharmacy needs and focuses on the needs of chronic patients. Chefaa claims to have fulfilled hundreds of thousands of orders. It serves chronic patients across all of Egypt. It manages their recurring treatment and delivers medication to the customers’ house from the nearest pharmacy.
With the outbreak of Covid-19, it has been working around the clock to help, serve and educate chronic patients
Doaa Aref, Co-Founder and CEO of Chefaa, said: “We intend to use this investment to grow our operations team to be working around the clock; 24/7 and to launch our B2B model to serve SMEs. We have also launched our private-labelled and white labelled products line. Chefaa is merging e-commerce, retail with the pharmaceutical industry and positioning itself to lead the change towards the safe digital transformation of the pharmaceutical industry. With the capital we have raised and support of partners like 500 startups, Vision ventures and womena, we are focused on scaling efficiently and sustainably. ”
Recently, the startup launched their private-labelled and white labelled products line.
Dr. Rasha Rady, Co-Founder and COO, said: “We have built our customer care center to ensure users’ experience is being professionally managed. We understand the impact of chronic illness as well as chronic patients’ needs and we intend to launch new services all designed around chronic patients’ lives.”
The startup raised a six-figure seed funding round from 500 startups, Flat6labs and 3 angel investors in August 2019.
If you see something out of place or would like to contribute to this story, check out our Ethics and Policy section.